KR20210141930A - 염증성 질환의 치료를 위한 아미노산 유도체 - Google Patents
염증성 질환의 치료를 위한 아미노산 유도체 Download PDFInfo
- Publication number
- KR20210141930A KR20210141930A KR1020217026302A KR20217026302A KR20210141930A KR 20210141930 A KR20210141930 A KR 20210141930A KR 1020217026302 A KR1020217026302 A KR 1020217026302A KR 20217026302 A KR20217026302 A KR 20217026302A KR 20210141930 A KR20210141930 A KR 20210141930A
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- compound
- alkyl
- mmol
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962795549P | 2019-01-22 | 2019-01-22 | |
US62/795,549 | 2019-01-22 | ||
US201962871951P | 2019-07-09 | 2019-07-09 | |
US62/871,951 | 2019-07-09 | ||
PCT/US2020/014636 WO2020154420A2 (en) | 2019-01-22 | 2020-01-22 | Amino acid derivatives for the treatment of inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20210141930A true KR20210141930A (ko) | 2021-11-23 |
Family
ID=69726748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020217026302A KR20210141930A (ko) | 2019-01-22 | 2020-01-22 | 염증성 질환의 치료를 위한 아미노산 유도체 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220081415A1 (zh) |
EP (1) | EP3924349A2 (zh) |
JP (1) | JP2022524571A (zh) |
KR (1) | KR20210141930A (zh) |
CN (1) | CN113614074A (zh) |
AU (1) | AU2020211980A1 (zh) |
BR (1) | BR112021014372A2 (zh) |
CA (1) | CA3127246A1 (zh) |
CL (1) | CL2021001944A1 (zh) |
CO (1) | CO2021010931A2 (zh) |
EC (1) | ECSP21062210A (zh) |
IL (1) | IL284980A (zh) |
MA (1) | MA54940A (zh) |
MX (1) | MX2021008748A (zh) |
SG (1) | SG11202107977TA (zh) |
WO (1) | WO2020154420A2 (zh) |
ZA (1) | ZA202105229B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210113184A (ko) | 2018-11-30 | 2021-09-15 | 코멧 테라퓨틱스, 인코포레이티드 | 사이클릭 판테테인 유도체 및 이들의 용도 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US6218390B1 (en) * | 1998-12-17 | 2001-04-17 | Synaptic Pharmaceutical Corporation | Morpholinone and morpholine derivatives and uses thereof |
EP2424850A1 (en) * | 2009-05-01 | 2012-03-07 | Profectus Biosciences, Inc. | Benzamide and naphthamide derivatives inhibiting nuclear factor- kap pa (b) - (nf-kb) |
-
2020
- 2020-01-22 CN CN202080021880.4A patent/CN113614074A/zh active Pending
- 2020-01-22 US US17/424,455 patent/US20220081415A1/en active Pending
- 2020-01-22 SG SG11202107977TA patent/SG11202107977TA/en unknown
- 2020-01-22 CA CA3127246A patent/CA3127246A1/en active Pending
- 2020-01-22 BR BR112021014372-6A patent/BR112021014372A2/pt unknown
- 2020-01-22 MA MA054940A patent/MA54940A/fr unknown
- 2020-01-22 JP JP2021543302A patent/JP2022524571A/ja active Pending
- 2020-01-22 KR KR1020217026302A patent/KR20210141930A/ko unknown
- 2020-01-22 WO PCT/US2020/014636 patent/WO2020154420A2/en unknown
- 2020-01-22 EP EP20708296.7A patent/EP3924349A2/en active Pending
- 2020-01-22 MX MX2021008748A patent/MX2021008748A/es unknown
- 2020-01-22 AU AU2020211980A patent/AU2020211980A1/en active Pending
-
2021
- 2021-07-20 IL IL284980A patent/IL284980A/en unknown
- 2021-07-22 CL CL2021001944A patent/CL2021001944A1/es unknown
- 2021-07-23 ZA ZA2021/05229A patent/ZA202105229B/en unknown
- 2021-08-19 CO CONC2021/0010931A patent/CO2021010931A2/es unknown
- 2021-08-20 EC ECSENADI202162210A patent/ECSP21062210A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2021010931A2 (es) | 2022-01-17 |
IL284980A (en) | 2021-09-30 |
SG11202107977TA (en) | 2021-08-30 |
US20220081415A1 (en) | 2022-03-17 |
JP2022524571A (ja) | 2022-05-09 |
CN113614074A (zh) | 2021-11-05 |
CL2021001944A1 (es) | 2022-05-06 |
WO2020154420A3 (en) | 2020-09-10 |
WO2020154420A2 (en) | 2020-07-30 |
AU2020211980A1 (en) | 2021-08-19 |
ZA202105229B (en) | 2022-12-21 |
WO2020154420A4 (en) | 2020-11-12 |
EP3924349A2 (en) | 2021-12-22 |
ECSP21062210A (es) | 2022-06-30 |
BR112021014372A2 (pt) | 2021-09-28 |
CA3127246A1 (en) | 2020-07-30 |
MA54940A (fr) | 2021-12-22 |
MX2021008748A (es) | 2022-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5828201B2 (ja) | ナフタレン誘導体 | |
TWI475020B (zh) | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
JP7228586B2 (ja) | キナーゼ阻害剤としてのアミノイミダゾピリダジン | |
MXPA06002723A (es) | Derivados de 2-piridona como inhibidores de neutrofilo elastasa y su uso. | |
JP2006518341A (ja) | ヒストンデアセチラーゼ(hdac)阻害剤としてのヒドロキサム酸誘導体 | |
RU2612138C2 (ru) | Новые производные пиразина | |
US9493412B2 (en) | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | |
AU2009220974A1 (en) | Azetidine derivatives | |
KR20160132495A (ko) | 카나비노이드 수용체 작용제로서 5,6-이치환된 피리딘-2-카복스아미드 | |
EP2138482A1 (en) | Bicyclic heterocyclic compound | |
EP2760840A1 (en) | Quinolinone carboxamide inhibitors of endothelial lipase | |
JP2016513103A (ja) | アルビシジン誘導体、その使用および合成 | |
JP2023548947A (ja) | ベンジルアミンまたはベンジルアルコール誘導体およびその用途 | |
US8993557B2 (en) | Pyridinedione carboxamide inhibitors of endothelial lipase | |
KR20110025970A (ko) | 트롬빈 억제제로서 사용하기 위한 신규 복소환 카복스아미드 | |
KR20210141930A (ko) | 염증성 질환의 치료를 위한 아미노산 유도체 | |
JP2023552655A (ja) | ボロン酸化合物 | |
WO2022122035A1 (zh) | 凝血因子XIa抑制剂及其制备方法和应用 | |
CN115260194B (zh) | 新型egfr降解剂 | |
CN102010425B (zh) | 1,4-二硫-7-氮杂螺[4,4]壬烷-8-羧酸衍生物类组蛋白去乙酰化酶抑制剂及其应用 | |
JP5665537B2 (ja) | ピラゾール3,5カルボキシレート誘導体、これらの調製および治療上の適用 | |
CN118146197A (zh) | 炔类化合物及其制备方法、药物组合物与应用 | |
TW201326139A (zh) | 新穎吡□衍生物 | |
WO2020119590A1 (zh) | 3-氰基吡啶类化合物、包含其的药物组合物及其制备方法和用途 | |
EA042124B1 (ru) | Аминоимидазопиридазины в качестве ингибиторов киназ |